Jill Furzer

Jill Furzer

Auto-generated profile, based on publicly available information

Jill Furzer

Institute of Health Policy, Management and Evaluation University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
JFJill Furzer
Jill Furzer
SGSumit Gupta
Sumit Gupta
Paul NathanPaul Nathan
Paul Nathan
TSTal Schechter
Tal Schechter
JPJason Pole
Jason Pole
PPPetros Pechlivanoglou
Petros Pechlivanoglou
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for 1 in 5 diagnoses.1-3 Developments in ALL treatment have dramatically improved survival rates throughout the last 20 years.4,5 Relapsed ALL has not seen the same advances, with 5-year survival rates of 20% to 60%, depending on relapse site and timing.6,7 Treatment for high-risk, relapsed pediatric ALL has involved hematopoietic stem cell transplant (HSCT). Outside of HSCT, salvage regimens generally consist of adapted combinations of front-line therapies.8 While HSCT was considered the only curative option in these high-risk situations, not all patients with relapsed ALL will be eligible for HSCT. Furthermore, HSCT is associated with significant morbidity and treatment-related mortality.9,10 Both graft vs host disease (GVHD) and relapses after HSCT are common.9,11,12 Hematopoietic stem cell transplant is also costly, with a first-year inpatient cost of almost CaD $230 000 (US $174 712) in Canada.13

28 June 2022 in Health Economics
Verified
Journal Article
Closed access
JFJill Furzer
Jill Furzer
EDElizabeth Dhuey
Elizabeth Dhuey
ALAudrey Laporte
Audrey Laporte

9 May 2019 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JFJill Furzer
Jill Furzer
LTLauren Tessier
Lauren Tessier
DHDavid Hodgson
David Hodgson
CCCecilia Cotton
Cecilia Cotton
Paul NathanPaul Nathan
Paul Nathan
PPPetros Pechlivanoglou
Petros Pechlivanoglou
Background: Adolescent women treated for Hodgkin lymphoma (HL) are at increased risk of breast cancer (BC). We evaluate the cost-utility of eight high-risk BC surveillance strategies for this population, including the Children’s Oncology Group guideline of same-day annual mammography and magnetic resonance imaging (MRI) beginning at age 25 years. Methods: A discrete event simulation model was used to simulate the life histories of a cohort of 500 000 25-year-old women treated for HL at age 15 years. We estimated BC incidence and mortality, life expectancy, quality-adjusted life-years (QALYs), health-care costs, and the relative cost-utility (incremental cost-utility ratio [ICUR]) under the eight assessed surveillance strategies. One-way sensitivity analysis enabled modeling of uncertainty evaluation. A publicly funded health-care payer perspective was adopted. Results: Costs across the eight screening strategies ranged from $32 643 to $43 739, whereas QALYs ranged from 24.419 to 24.480. In an incremental cost-effectiveness analysis, annual mammography beginning at age 25 years was associated with an ICUR of $43 000/QALY gained, annual MRI beginning at age 25 years with a switch to annual mammography at age 50 years had an ICUR of $148 000/QALY, and annual MRI beginning at age 25 years had an ICUR of $227 222/QALY. Among all assessed surveillance strategies, the differences in life expectancy were small. Conclusions: Current high-risk BC surveillance guidelines do not reflect the most cost-effective strategy in survivors of adolescent HL. The results suggest that groups at high risk of BC may require high-risk surveillance guidelines that reflect their specific risk profile.